Calcitonin gene-related peptide monoclonal antibody

Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.

Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.

Drugs
Currently FDA-licensed CGRP mAbs are:
 * Eptinezumab (Vyepti), approved in 2020
 * Erenumab (Aimovig), approved in 2018
 * Fremanezumab (Ajovy), approved in 2018
 * Galcanezumab (Emgality), approved in 2018

News and articles

 * 2020, Can migraines be untangled by new medical thinking? - The Observer

Learn more

 * Calcitonin gene-related peptide monoclonal antibodies - The Migraine Trust